HC Wainwright Comments on GH Research FY2030 Earnings

GH Research PLC (NASDAQ:GHRS) – Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for GH Research in a report released on Monday, March 2nd. HC Wainwright analyst P. Trucchio anticipates that the company will earn $1.54 per share for the year. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06.

Other equities analysts have also issued reports about the company. Canaccord Genuity Group boosted their price target on GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research note on Thursday, January 22nd. Needham & Company LLC set a $29.00 price target on shares of GH Research in a report on Tuesday, January 6th. TD Cowen reiterated a “buy” rating on shares of GH Research in a report on Monday, January 5th. Finally, Wall Street Zen cut shares of GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GH Research currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.75.

GH Research Price Performance

NASDAQ GHRS opened at $15.17 on Wednesday. The business has a 50 day simple moving average of $15.38 and a 200 day simple moving average of $14.21. GH Research has a one year low of $7.98 and a one year high of $19.51. The stock has a market capitalization of $789.30 million, a P/E ratio of -20.50 and a beta of 1.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new stake in shares of GH Research during the second quarter worth about $79,000. Virtus Investment Advisers LLC bought a new stake in GH Research during the 2nd quarter worth approximately $89,000. Stempoint Capital LP purchased a new stake in shares of GH Research in the second quarter worth approximately $1,229,000. HighVista Strategies LLC bought a new position in shares of GH Research in the second quarter valued at approximately $637,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares in the last quarter. 56.90% of the stock is owned by institutional investors.

More GH Research News

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company business update: GHRS reported completion of the Phase 2b trial of GH001 in treatment‑resistant depression, presented the full dataset at ASCP and ECNP, and announced FDA clearance to begin U.S. clinical investigations (allowing U.S. enrollment). The update also showed cash, cash equivalents and marketable securities of $280.7M at year‑end — supportive for near‑term development funding. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly results beat: GHRS reported EPS of ($0.23) for the quarter, beating consensus ($0.29) — a modest operational beat that can be viewed as a short‑term positive. Press Release
• Positive Sentiment: Analyst support: HC Wainwright retains a Buy rating and a $70 price target; an article also notes a $70 price‑target raise reported by coverage outlets — this maintains a constructive longer‑term analyst stance. Price Target Raised to $70.00
• Neutral Sentiment: Short‑interest note: the published short‑interest snapshot shows effectively zero reported short position and a 0.0 days‑to‑cover figure — data appears noisy/insignificant and is not clearly informative for immediate directional pressure.
• Neutral Sentiment: Long‑range projection: HC Wainwright issued a FY2030 EPS forecast of $1.54 per share — a distant, model‑dependent projection that provides upside in scenarios where development and commercialization succeed but has limited near‑term impact. HC Wainwright estimates (MarketBeat)
• Negative Sentiment: Multi‑year estimate cuts: HC Wainwright cut EPS forecasts across Q4 2025 and FY2025–FY2028 (and adjusted FY2026–FY2027 materially lower), reflecting a more conservative near‑to‑mid term earnings outlook; these downward revisions are a primary near‑term negative catalyst for the stock. HC Wainwright estimates (MarketBeat)

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.